14.12.2012 - After decades of deadlock, Europe is finally set to get a new unified patent. This week the Competitiveness Council and MEPs adopted the draft law.
Provided the draft law will be signed by at least 13 EU member states, EU patents must be only translated into three languages cutting the cost drastically. Today, two thirds of the patent cost of €36,000 is translation cost. The new unitary patent is calculated to cost a maximum of only €6,425, with the costs of translation set to range from €680 to €2,380. However, this is still twice as expensive as an US patent. “Today’s vote is good news for the EU economy and especially for small and medium-sized enterprises (SMEs),” said MEP Bernhard Rapkay.
Italian MEP Raffaele Baldassarre, who had been leading negotiations on the new translation regime, described the current cost burden as “effectively a tax on innovation. We have to understand that there is a need out there to facilitate innovation in the EU."
Under the new scheme, patent applications will have to be made in either English, French or German – and will be made available in the same three languages. MEPs also voted to fully reimburse translation costs for EU-based SMEs, non-profit organisations, universities and public research organisations - something expected to benefit small high-tech firms in particular.Renewal fees, which are responsible for much of the overall cost of the current European system, will also be set at a level to help SMEs.
“Spain and Italy have so far opted out of the unitary patent package, but could join in the decision-making process at any time,” the Parliament says. “This procedure was used to break a deadlock, mainly due to language issues, that lasted over thirty yearsThe agreement is expected to be signed in February next year, and it will come into force on 1 January 2014 or when at least 13 member states including the UK, France and Germany have ratified it. Patents on plants have been excluded from the law, previously. The legislation still has to be formally adopted by the Council, but this will take place shortly.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.